ArticleAsian Pacific journal of cancer prevention : APJCP2025
Immunoscore CD3/CD8 and FOXP3 Expression Correlate to Neoadjuvant Chemotherapy Response in Triple Negative Breast Cancer: A Case-Control Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the significance of diminished CD3/CD8 and CD3/CDR45RO immunoscores, as well as elevated FOXP3 expression, as potential risk factors for unfavorable responses to neoadjuvant chemotherapy among patients with triple-negative breast cancer (TNBC).
methodsA case-control study was conducted across two hospitals (a public and a private facility) from August 1st, 2021, to August 31st, 2022. The study population comprised patients diagnosed with the TNBC subtype, with available paraffin blocks from biopsy procedures. Immunohistochemical staining was performed on specimens for CD3, CD8, CD45RO, and FOXP3 antibodies.
resultsA total of seventy-two patients were enrolled in the study, among whom seven patients (16.7%) achieved a pathological complete response to neoadjuvant chemotherapy (NAC). Notably, there existed a significant correlation between CD3/CD8 and CD3/CD45RO immunoscores, as well as FOXP3 expression, and NAC response (p<0.05). Multivariate analysis involving 70 samples from the case-control study revealed that a diminished CD3/CD8 immunoscore (aOR=10.930; 95% CI=1.336-89.420) and heightened FOXP3 expression (aOR=11.775; 95% CI =2.537-54.656) independently posed as risk factors for unfavorable NAC response (p<0.05). However, the CD3/CD45RO immunoscore did not emerge as an independent risk factor for NAC response.
conclusionsA reduced CD3/CD8 immunoscore and elevated FOXP3 expression stand as autonomous risk factors for suboptimal NAC response in patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.